University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:
Augurex Announces Agreement with ARUP Laboratories to Expand Access to Advanced Rheumatoid Arthritis Diagnosis with the Launch of 14-3-3η (eta) Test
Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, announced that ARUP Laboratories, a leading national reference laboratory in the U.S., has launched the 14-3-3η test as part of their diagnostic testing portfolio. This agreement is poised to significantly enhance the early detection and management of rheumatoid arthritis (RA), providing clinicians with an important tool to improve patient care and outcomes.
Epitel Expands AI Portfolio With A Fourth FDA 510(k) Clearance for REMI
Epitel, a leader in AI for patient-focused brain health technologies, announced it received U.S. Food and Drug Administration (FDA) 510(k) clearance for REMI Vigilenz™ AI For Bedside Notifications. REMI Vigilenz AI For Bedside Notifications conducts an automated analysis of EEG data collected by the REMI™ wireless wearable EEG System in near real-time. Notifications occur when the algorithm recognizes seizure characteristics within a section of EEG. These notifications provide information about the potential electrographic seizure, including seizure burden and corresponding confidence level.
Turner MedTech Announces MOU for Contract Manufacturing for KyphoLift™ MRI Device
Turner MedTech, a leading contract manufacturer of medical devices, announced it has signed a Memorandum of Understanding with KyphoLift™ to manufacture its innovative MRI device designed to improve patient comfort and efficiency during scans. The KyphoLift device helps position patients with spinal injuries, fusions, degenerative disk disease, and kyphosis for more accurate imaging.
Light Line Medical places 2nd in the SCI Innovation Competition
Light Line Medical’s PhotoDisinfection System, which uses visible light to prevent infection, won second place in the 8th SCI Innovation Competition on October 19, 2024 in Toronto. As a winner, Light Line has been awarded a trade mission to China to meet with investors, supply chain partners and customers in late November 2024.
Recursion and Google Cloud Announce Expansion of Partnership to Support Drug Discovery with Cloud and Exploration of Generative AI Technologies
Recursion, a leading TechBio company decoding biology to radically improve lives, and Google Cloud announced an expanded collaboration leveraging Google Cloud's technologies to support Recursion's drug discovery platform.
Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection
Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecule and new chemical entity for the treatment of recurrent Clostridioides difficile infection. C. diff is a toxin producing bacteria that causes diarrhea and colitis, and can be life threatening. Up to 730,000 cases are estimated to occur in the U.S. and EU5 annually, and the infection is responsible for an estimated 29,000 deaths in the U.S. each year. Recursion’s study will initially address the recurrent C. diff. (up to 175,000 cases in the United States per year) population, which costs the healthcare system approximately two billion dollars per year.
